Kedrion Biopharma receives US FDA orphan drug designation for Coagadex to treat acquired Factor X deficiency

Kedrion Biopharma, a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies, announced that the US Food and Drug Administration

To access the full article, please log in or subscribe.